+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Brain & Spinal Cord Cancer Market - Global Forecast to 2030- Product Image
Brain & Spinal Cord Cancer Market - Global Forecast to 2030- Product Image
Sale

Brain & Spinal Cord Cancer Market - Global Forecast to 2030

  • PDF Icon

    Report

  • 182 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5968082
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Brain & Spinal Cord Cancer Market grew from USD 3.98 billion in 2024 to USD 4.21 billion in 2025. It is expected to continue growing at a CAGR of 5.82%, reaching USD 5.59 billion by 2030.

Brain and spinal cord cancers present some of the most complex challenges in neuro-oncology, demanding a nuanced understanding of tumor biology, advanced diagnostics, and innovative treatment modalities. Increasing incidence rates coupled with a diverse range of histological subtypes underscore the urgency for tailored therapeutic strategies. Recent breakthroughs in molecular profiling and precision medicine have sharpened our ability to classify tumors more accurately, enabling clinicians to select interventions that maximize efficacy while minimizing collateral damage to healthy neural tissue. However, these advances also reveal gaps in patient access and highlight persistent barriers related to regulatory frameworks, reimbursement pathways, and supply chain dynamics.

Against this backdrop, a comprehensive overview of the current landscape is essential for stakeholders seeking to align their strategies with evolving scientific and policy trends. This executive summary synthesizes key developments shaping research and commercialization efforts across major cancer types, treatment modalities, and end-user segments. It also examines the implications of impending tariff adjustments, regional market nuances, and the competitive positioning of leading industry participants. By contextualizing these findings, decision-makers can better anticipate opportunities for collaboration, investment, and clinical innovation, ultimately driving improved outcomes for patients coping with brain and spinal cord malignancies.

Transformative Shifts Reshaping Neuro-Oncology

The neuro-oncology field has experienced several transformative shifts, driven primarily by advances in genomics, immunotherapeutics, and digital health. First, the integration of next-generation sequencing into routine diagnostics has enabled the identification of actionable mutations across diverse tumor subtypes, from astrocytomas to medulloblastomas. This shift toward precision profiling has laid the groundwork for targeted therapies that exploit specific molecular pathways.

Second, immunotherapy has emerged as a disruptive force. Checkpoint inhibitors and personalized cancer vaccines have begun to demonstrate durable responses in select patient cohorts, challenging the dominance of conventional cytotoxic regimens. Third, the convergence of artificial intelligence with medical imaging has accelerated lesion detection and treatment planning, reducing diagnostic latency and facilitating adaptive radiotherapy approaches. Finally, collaborative research consortia have fostered multi-institutional clinical trials, broadening the evidence base for rare CNS lymphomas and metastatic brain tumors. Together, these developments are reshaping clinical algorithms, reallocating R&D investments, and redefining the competitive landscape for both established players and agile newcomers.

Evaluating the 2025 U.S. Tariff Impacts on Neuro-Oncology

In 2025, the introduction of revised United States tariffs on pharmaceutical imports is set to exert multifaceted effects on the neuro-oncology sector. Tariff adjustments will influence manufacturing costs by raising duties on critical raw materials, including specialized reagents used in antibody production and radiopharmaceutical components. These cost increases are likely to propagate through the supply chain, potentially elevating prices for immunotherapies, targeted agents, and diagnostic kits.

Moreover, tariffs may incentivize manufacturers to localize production or source inputs domestically, sparking capacity expansions at U.S.-based bioprocessing facilities. While this could mitigate supply risks, it also requires significant capital investment and regulatory approval timelines. Meanwhile, higher import duties on advanced imaging equipment may slow the deployment of cutting-edge radiotherapy platforms, delaying access to external beam and internal radiation innovations. To navigate these headwinds, companies must engage proactively with policymakers and explore strategic partnerships that optimize production footprints. By doing so, stakeholders can balance cost management with sustained investment in clinical research and patient care.

Comprehensive Market Segmentation Analysis

A granular understanding of market segmentation reveals critical pathways for growth and differentiation. When examining cancer types, gliomas encompass astrocytomas, ependymomas, and oligodendrogliomas, each with distinct molecular signatures and therapeutic vulnerabilities. Metastatic brain tumors focus on secondary malignancies that originate elsewhere in the body, posing unique challenges in systemic control and blood-brain barrier penetration. Non-gliomas cover CNS lymphomas, medulloblastomas, and meningiomas, where tailored immunotherapeutic and targeted strategies are gaining momentum.

Turning to treatment modalities, chemotherapy remains a cornerstone, particularly with alkylating agents and antimetabolites driving cytotoxic efficacy. However, immunotherapy is redefining standards of care, with cancer vaccines and checkpoint inhibitors demonstrating potential in refractory cases. Radiation therapy continues to evolve through external beam and internal radiation innovations, offering precision dosing that spares healthy tissue. Surgical interventions, including biopsy and craniotomy, maintain their central role in diagnosis and debulking, while targeted therapies-spanning monoclonal antibodies to small molecule inhibitors-address specific oncogenic drivers.

Finally, end users span clinics, diagnostic centers, hospitals, and research and academic institutes. Clinics provide ongoing patient management and supportive care, whereas diagnostic centers specialize in advanced imaging and biomarker analysis. Hospitals integrate multidisciplinary teams for comprehensive treatment protocols, and research and academic institutes spearhead early-stage studies, driving the discovery of next-generation diagnostics and therapeutics.

Key Regional Dynamics Influencing Growth

Regional dynamics are shaping investment priorities and access to care across the globe. In the Americas, robust healthcare infrastructure and established regulatory pathways facilitate rapid adoption of immunotherapies and precision diagnostics. Emerging telemedicine initiatives are expanding outreach, particularly in under-served areas, and public-private partnerships are accelerating clinical trial enrollment. Meanwhile, Europe, the Middle East, and Africa (EMEA) present a heterogeneous landscape: Western European markets benefit from high per-capita healthcare spending and coordinated cross-border research consortia, whereas many countries in the Middle East and Africa face resource constraints that impede access to advanced treatment modalities. Collaboration with global foundations and tiered pricing models are increasingly critical for expanding patient access.

In the Asia-Pacific region, rapid economic growth and sizable patient populations have attracted significant R&D investment. Countries such as Japan and South Korea lead in proton therapy and minimally invasive neurosurgical techniques, while markets in China and India are scaling domestic manufacturing to meet rising demand for generic chemotherapeutics and biosimilars. Government initiatives aimed at integrating artificial intelligence into oncology workflows further distinguish the Asia-Pacific landscape. These regional insights underscore the importance of tailored market entry strategies and local partnerships to optimize both commercial traction and patient impact.

Competitive Landscape and Company Profiles

The competitive ecosystem comprises a diverse array of pharmaceutical, biotechnology, and medical technology leaders. Amgen Inc. and Bayer AG are advancing targeted therapies that inhibit specific signaling pathways implicated in tumor proliferation. Bluebird bio is focused on gene therapy approaches, while Bristol Myers Squibb is expanding its immuno-oncology portfolio through checkpoint inhibitor trials. Dr. Reddy’s Laboratories and Teva Pharmaceutical Industries are notable for their expertise in generic chemotherapeutic agents, addressing cost pressures in both mature and emerging markets.

Eisai Inc., F. Hoffmann-La Roche Ltd., and Genentech are at the forefront of companion diagnostics and targeted monoclonal antibody therapies. GlaxoSmithKline and Merck & Co. are pioneering cancer vaccines and combination regimens, leveraging their extensive clinical trial networks. Illumina leads the genomics space with advanced sequencing platforms that underpin precision medicine initiatives, whereas Johnson & Johnson and Novartis AG integrate digital health tools into their therapeutic ecosystems.

Nektar Therapeutics and Regeneron Pharmaceuticals are investing heavily in novel immunomodulators, while Pfizer Inc. and Y-mAbs Therapeutics advance antibody-drug conjugates designed for central nervous system penetration. Shimadzu Corporation and Siemens Healthineers supply the imaging and radiotherapy hardware essential for accurate diagnosis and treatment planning. Collectively, these companies are shaping the future of neuro-oncology through strategic alliances, M&A activity, and a relentless focus on R&D excellence.

Actionable Recommendations for Market Leadership

To maintain a competitive edge, industry leaders should prioritize several strategic imperatives. First, invest in precision diagnostics by partnering with genomics and imaging providers to deliver comprehensive molecular profiling solutions. This will enable clinicians to stratify patients effectively and tailor treatment protocols. Second, diversify portfolios through targeted immunotherapy collaborations that combine checkpoint inhibitors with vaccine platforms, amplifying clinical efficacy.

Third, optimize supply chain resilience by geographically diversifying manufacturing sites and securing alternative sourcing agreements for key raw materials. Fourth, engage proactively with regulatory bodies to streamline approval processes for novel therapeutics and diagnostics, leveraging real-world evidence to support expedited pathways. Fifth, design flexible pricing models that address affordability concerns in resource-limited regions while preserving commercial viability in high-income markets.

Finally, strengthen digital health capabilities by integrating telemedicine, remote monitoring, and AI-driven decision support into patient care pathways. By aligning these initiatives across R&D, commercialization, and patient engagement, leaders can drive sustained innovation and deliver measurable improvements in patient outcomes.

Conclusion and Strategic Takeaways

The neuro-oncology sector stands at an inflection point, propelled by breakthroughs in molecular science, immunotherapy, and digital health. As stakeholders navigate evolving regulatory landscapes and shifting payer dynamics, a clear understanding of market segmentation, regional nuances, and competitive positioning is essential. Strategic investments in precision diagnostics, diversified treatment portfolios, and resilient supply chains will be crucial for long-term success. Collaboration with cross-sector partners and proactive engagement with policymakers can further accelerate patient access and foster an environment conducive to innovation.

By adopting a holistic approach that integrates scientific rigor with commercial acumen, organizations can seize emerging opportunities and address unmet needs across the brain and spinal cord cancer continuum. The insights presented here provide a foundation for data-driven decision-making, enabling agile adaptation to market disruptions and sustained growth in an increasingly complex therapeutic landscape.

Market Segmentation & Coverage

This research report categorizes the Brain & Spinal Cord Cancer Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Gliomas
    • Astrocytomas
    • Ependymomas
    • Oligodendrogliomas
  • Metastatic Brain Tumors
    • Secondary Brain Cancers
  • Non-Gliomas
    • CNS Lymphomas
    • Medulloblastomas
    • Meningiomas
  • Chemotherapy
    • Alkylating Agents
    • Antimetabolites
  • Immunotherapy
    • Cancer Vaccines
    • Checkpoint Inhibitors
  • Radiation Therapy
    • External Beam
    • Internal Radiation
  • Surgery
    • Biopsy
    • Craniotomy
  • Targeted Therapy
    • Monoclonal Antibodies
    • Small Molecule Inhibitors
  • Clinics
  • Diagnostic Centers
  • Hospitals
  • Research & Academic Institutes

This research report categorizes the Brain & Spinal Cord Cancer Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Brain & Spinal Cord Cancer Market to delves into recent significant developments and analyze trends in each of the following companies:

  • Amgen Inc.
  • Bayer AG
  • bluebird bio, Inc.
  • Bristol Myers Squibb Company
  • Dr. Reddy’s Laboratories Ltd.
  • Eisai Inc.
  • F. Hoffmann-La Roche Ltd.
  • Genentech, Inc.
  • GlaxoSmithKline PLC
  • Illumina, Inc.
  • Johnson & Johnson Services, Inc
  • Merck & Co., Inc.
  • Nektar Therapeutics
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Shimadzu Corporation
  • Siemens Healthineers
  • Teva Pharmaceutical Industries Ltd.
  • Y-mAbs Therapeutics A/S

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Brain & Spinal Cord Cancer Market, by Cancer Type
8.1. Introduction
8.2. Gliomas
8.2.1. Astrocytomas
8.2.2. Ependymomas
8.2.3. Oligodendrogliomas
8.3. Metastatic Brain Tumors
8.3.1. Secondary Brain Cancers
8.4. Non-Gliomas
8.4.1. CNS Lymphomas
8.4.2. Medulloblastomas
8.4.3. Meningiomas
9. Brain & Spinal Cord Cancer Market, by Treatment Type
9.1. Introduction
9.2. Chemotherapy
9.2.1. Alkylating Agents
9.2.2. Antimetabolites
9.3. Immunotherapy
9.3.1. Cancer Vaccines
9.3.2. Checkpoint Inhibitors
9.4. Radiation Therapy
9.4.1. External Beam
9.4.2. Internal Radiation
9.5. Surgery
9.5.1. Biopsy
9.5.2. Craniotomy
9.6. Targeted Therapy
9.6.1. Monoclonal Antibodies
9.6.2. Small Molecule Inhibitors
10. Brain & Spinal Cord Cancer Market, by End User
10.1. Introduction
10.2. Clinics
10.3. Diagnostic Centers
10.4. Hospitals
10.5. Research & Academic Institutes
11. Americas Brain & Spinal Cord Cancer Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Brain & Spinal Cord Cancer Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Brain & Spinal Cord Cancer Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. Market Share Analysis, 2024
14.2. FPNV Positioning Matrix, 2024
14.3. Competitive Analysis
14.3.1. Amgen Inc.
14.3.2. Bayer AG
14.3.3. bluebird bio, Inc.
14.3.4. Bristol Myers Squibb Company
14.3.5. Dr. Reddy’s Laboratories Ltd.
14.3.6. Eisai Inc.
14.3.7. F. Hoffmann-La Roche Ltd.
14.3.8. Genentech, Inc.
14.3.9. GlaxoSmithKline PLC
14.3.10. Illumina, Inc.
14.3.11. Johnson & Johnson Services, Inc
14.3.12. Merck & Co., Inc.
14.3.13. Nektar Therapeutics
14.3.14. Novartis AG
14.3.15. Pfizer Inc.
14.3.16. Regeneron Pharmaceuticals, Inc.
14.3.17. Shimadzu Corporation
14.3.18. Siemens Healthineers
14.3.19. Teva Pharmaceutical Industries Ltd.
14.3.20. Y-mAbs Therapeutics A/S
15. ResearchAI
16. ResearchStatistics
17. ResearchContacts
18. ResearchArticles
19. Appendix
List of Figures
FIGURE 1. BRAIN & SPINAL CORD CANCER MARKET MULTI-CURRENCY
FIGURE 2. BRAIN & SPINAL CORD CANCER MARKET MULTI-LANGUAGE
FIGURE 3. BRAIN & SPINAL CORD CANCER MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. BRAIN & SPINAL CORD CANCER MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. BRAIN & SPINAL CORD CANCER MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. BRAIN & SPINAL CORD CANCER MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY GLIOMAS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY ASTROCYTOMAS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY EPENDYMOMAS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY OLIGODENDROGLIOMAS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY GLIOMAS, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY METASTATIC BRAIN TUMORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SECONDARY BRAIN CANCERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY METASTATIC BRAIN TUMORS, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY NON-GLIOMAS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CNS LYMPHOMAS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MEDULLOBLASTOMAS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MENINGIOMAS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY NON-GLIOMAS, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY EXTERNAL BEAM, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY INTERNAL RADIATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY BIOPSY, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CRANIOTOMY, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY GLIOMAS, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY METASTATIC BRAIN TUMORS, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY NON-GLIOMAS, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 58. ARGENTINA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 59. ARGENTINA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY GLIOMAS, 2018-2030 (USD MILLION)
TABLE 60. ARGENTINA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY METASTATIC BRAIN TUMORS, 2018-2030 (USD MILLION)
TABLE 61. ARGENTINA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY NON-GLIOMAS, 2018-2030 (USD MILLION)
TABLE 62. ARGENTINA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 63. ARGENTINA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 64. ARGENTINA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 65. ARGENTINA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 66. ARGENTINA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 67. ARGENTINA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 68. ARGENTINA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 69. BRAZIL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 70. BRAZIL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY GLIOMAS, 2018-2030 (USD MILLION)
TABLE 71. BRAZIL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY METASTATIC BRAIN TUMORS, 2018-2030 (USD MILLION)
TABLE 72. BRAZIL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY NON-GLIOMAS, 2018-2030 (USD MILLION)
TABLE 73. BRAZIL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 74. BRAZIL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 75. BRAZIL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 76. BRAZIL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 77. BRAZIL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 78. BRAZIL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 79. BRAZIL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 80. CANADA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 81. CANADA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY GLIOMAS, 2018-2030 (USD MILLION)
TABLE 82. CANADA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY METASTATIC BRAIN TUMORS, 2018-2030 (USD MILLION)
TABLE 83. CANADA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY NON-GLIOMAS, 2018-2030 (USD MILLION)
TABLE 84. CANADA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 85. CANADA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 86. CANADA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 87. CANADA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 88. CANADA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 89. CANADA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 90. CANADA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 91. MEXICO BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 92. MEXICO BRAIN & SPINAL CORD CANCER MARKET SIZE, BY GLIOMAS, 2018-2030 (USD MILLION)
TABLE 93. MEXICO BRAIN & SPINAL CORD CANCER MARKET SIZE, BY METASTATIC BRAIN TUMORS, 2018-2030 (USD MILLION)
TABLE 94. MEXICO BRAIN & SPINAL CORD CANCER MARKET SIZE, BY NON-GLIOMAS, 2018-2030 (USD MILLION)
TABLE 95. MEXICO BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 96. MEXICO BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 97. MEXICO BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 98. MEXICO BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 99. MEXICO BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 100. MEXICO BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 101. MEXICO BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 102. UNITED STATES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 103. UNITED STATES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY GLIOMAS, 2018-2030 (USD MILLION)
TABLE 104. UNITED STATES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY METASTATIC BRAIN TUMORS, 2018-2030 (USD MILLION)
TABLE 105. UNITED STATES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY NON-GLIOMAS, 2018-2030 (USD MILLION)
TABLE 106. UNITED STATES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 107. UNITED STATES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 108. UNITED STATES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 109. UNITED STATES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 110. UNITED STATES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 111. UNITED STATES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 112. UNITED STATES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 113. UNITED STATES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 114. ASIA-PACIFIC BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 115. ASIA-PACIFIC BRAIN & SPINAL CORD CANCER MARKET SIZE, BY GLIOMAS, 2018-2030 (USD MILLION)
TABLE 116. ASIA-PACIFIC BRAIN & SPINAL CORD CANCER MARKET SIZE, BY METASTATIC BRAIN TUMORS, 2018-2030 (USD MILLION)
TABLE 117. ASIA-PACIFIC BRAIN & SPINAL CORD CANCER MARKET SIZE, BY NON-GLIOMAS, 2018-2030 (USD MILLION)
TABLE 118. ASIA-PACIFIC BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 119. ASIA-PACIFIC BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 120. ASIA-PACIFIC BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 121. ASIA-PACIFIC BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 122. ASIA-PACIFIC BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 123. ASIA-PACIFIC BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 124. ASIA-PACIFIC BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 125. ASIA-PACIFIC BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 126. AUSTRALIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 127. AUSTRALIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY GLIOMAS, 2018-2030 (USD MILLION)
TABLE 128. AUSTRALIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY METASTATIC BRAIN TUMORS, 2018-2030 (USD MILLION)
TABLE 129. AUSTRALIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY NON-GLIOMAS, 2018-2030 (USD MILLION)
TABLE 130. AUSTRALIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 131. AUSTRALIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 132. AUSTRALIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 133. AUSTRALIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 134. AUSTRALIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 135. AUSTRALIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 136. AUSTRALIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 137. CHINA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 138. CHINA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY GLIOMAS, 2018-2030 (USD MILLION)
TABLE 139. CHINA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY METASTATIC BRAIN TUMORS, 2018-2030 (USD MILLION)
TABLE 140. CHINA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY NON-GLIOMAS, 2018-2030 (USD MILLION)
TABLE 141. CHINA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 142. CHINA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 143. CHINA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 144. CHINA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 145. CHINA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 146. CHINA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 147. CHINA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 148. INDIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 149. INDIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY GLIOMAS, 2018-2030 (USD MILLION)
TABLE 150. INDIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY METASTATIC BRAIN TUMORS, 2018-2030 (USD MILLION)
TABLE 151. INDIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY NON-GLIOMAS, 2018-2030 (USD MILLION)
TABLE 152. INDIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 153. INDIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 154. INDIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 155. INDIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 156. INDIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 157. INDIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 158. INDIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 159. INDONESIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 160. INDONESIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY GLIOMAS, 2018-2030 (USD MILLION)
TABLE 161. INDONESIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY METASTATIC BRAIN TUMORS, 2018-2030 (USD MILLION)
TABLE 162. INDONESIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY NON-GLIOMAS, 2018-2030 (USD MILLION)
TABLE 163. INDONESIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 164. INDONESIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 165. INDONESIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 166. INDONESIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 167. INDONESIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 168. INDONESIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 169. INDONESIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 170. JAPAN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 171. JAPAN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY GLIOMAS, 2018-2030 (USD MILLION)
TABLE 172. JAPAN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY METASTATIC BRAIN TUMORS, 2018-2030 (USD MILLION)
TABLE 173. JAPAN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY NON-GLIOMAS, 2018-2030 (USD MILLION)
TABLE 174. JAPAN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 175. JAPAN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 176. JAPAN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 177. JAPAN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 178. JAPAN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 179. JAPAN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 180. JAPAN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 181. MALAYSIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 182. MALAYSIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY GLIOMAS, 2018-2030 (USD MILLION)
TABLE 183. MALAYSIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY METASTATIC BRAIN TUMORS, 2018-2030 (USD MILLION)
TABLE 184. MALAYSIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY NON-GLIOMAS, 2018-2030 (USD MILLION)
TABLE 185. MALAYSIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 186. MALAYSIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 187. MALAYSIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 188. MALAYSIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 189. MALAYSIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 190. MALAYSIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 191. MALAYSIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 192. PHILIPPINES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 193. PHILIPPINES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY GLIOMAS, 2018-2030 (USD MILLION)
TABLE 194. PHILIPPINES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY METASTATIC BRAIN TUMORS, 2018-2030 (USD MILLION)
TABLE 195. PHILIPPINES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY NON-GLIOMAS, 2018-2030 (USD MILLION)
TABLE 196. PHILIPPINES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 197. PHILIPPINES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 198. PHILIPPINES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 199. PHILIPPINES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 200. PHILIPPINES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 201. PHILIPPINES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 202. PHILIPPINES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 203. SINGAPORE BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 204. SINGAPORE BRAIN & SPINAL CORD CANCER MARKET SIZE, BY GLIOMAS, 2018-2030 (USD MILLION)
TABLE 205. SINGAPORE BRAIN & SPINAL CORD CANCER MARKET SIZE, BY METASTATIC BRAIN TUMORS, 2018-2030 (USD MILLION)
TABLE 206. SINGAPORE BRAIN & SPINAL CORD CANCER MARKET SIZE, BY NON-GLIOMAS, 2018-2030 (USD MILLION)
TABLE 207. SINGAPORE BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 208. SINGAPORE BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 209. SINGAPORE BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 210. SINGAPORE BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 211. SINGAPORE BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 212. SINGAPORE BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 213. SINGAPORE BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 214. SOUTH KOREA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 215. SOUTH KOREA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY GLIOMAS, 2018-2030 (USD MILLION)
TABLE 216. SOUTH KOREA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY METASTATIC BRAIN TUMORS, 2018-2030 (USD MILLION)
TABLE 217. SOUTH KOREA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY NON-GLIOMAS, 2018-2030 (USD MILLION)
TABLE 218. SOUTH KOREA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 219. SOUTH KOREA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 220. SOUTH KOREA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 221. SOUTH KOREA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 222. SOUTH KOREA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 223. SOUTH KOREA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 224. SOUTH KOREA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 225. TAIWAN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 226. TAIWAN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY GLIOMAS, 2018-2030 (USD MILLION)
TABLE 227. TAIWAN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY METASTATIC BRAIN TUMORS, 2018-2030 (USD MILLION)
TABLE 228. TAIWAN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY NON-GLIOMAS, 2018-2030 (USD MILLION)
TABLE 229. TAIWAN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 230. TAIWAN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 231. TAIWAN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 232. TAIWAN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 233. TAIWAN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 234. TAIWAN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 235. TAIWAN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 236. THAILAND BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 237. THAILAND BRAIN & SPINAL CORD CANCER MARKET SIZE, BY GLIOMAS, 2018-2030 (USD MILLION)
TABLE 238. THAILAND BRAIN & SPINAL CORD CANCER MARKET SIZE, BY METASTATIC BRAIN TUMORS, 2018-2030 (USD MILLION)
TABLE 239. THAILAND BRAIN & SPINAL CORD CANCER MARKET SIZE, BY NON-GLIOMAS, 2018-2030 (USD MILLION)
TABLE 240. THAILAND BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 241. THAILAND BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 242. THAILAND BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 243. THAILAND BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 244. THAILAND BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 245. THAILAND BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 246. THAILAND BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 247. VIETNAM BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 248. VIETNAM BRAIN & SPINAL CORD CANCER MARKET SIZE, BY GLIOMAS, 2018-2030 (USD MILLION)
TABLE 249. VIETNAM BRAIN & SPINAL CORD CANCER MARKET SIZE, BY METASTATIC BRAIN TUMORS, 2018-2030 (USD MILLION)
TABLE 250. VIETNAM BRAIN & SPINAL CORD CANCER MARKET SIZE, BY NON-GLIOMAS, 2018-2030 (USD MILLION)
TABLE 251. VIETNAM BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 252. VIETNAM BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 253. VIETNAM BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 254. VIETNAM BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 255. VIETNAM BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 256. VIETNAM BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 257. VIETNAM BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 258. EUROPE, MIDDLE EAST & AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 259. EUROPE, MIDDLE EAST & AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY GLIOMAS, 2018-2030 (USD MILLION)
TABLE 260. EUROPE, MIDDLE EAST & AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY METASTATIC BRAIN TUMORS, 2018-2030 (USD MILLION)
TABLE 261. EUROPE, MIDDLE EAST & AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY NON-GLIOMAS, 2018-2030 (USD MILLION)
TABLE 262. EUROPE, MIDDLE EAST & AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 263. EUROPE, MIDDLE EAST & AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 264. EUROPE, MIDDLE EAST & AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 265. EUROPE, MIDDLE EAST & AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 266. EUROPE, MIDDLE EAST & AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 267. EUROPE, MIDDLE EAST & AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 268. EUROPE, MIDDLE EAST & AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 269. EUROPE, MIDDLE EAST & AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 270. DENMARK BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 271. DENMARK BRAIN & SPINAL CORD CANCER MARKET SIZE, BY GLIOMAS, 2018-2030 (USD MILLION)
TABLE 272. DENMARK BRAIN & SPINAL CORD CANCER MARKET SIZE, BY METASTATIC BRAIN TUMORS, 2018-2030 (USD MILLION)
TABLE 273. DENMARK BRAIN & SPINAL CORD CANCER MARKET SIZE, BY NON-GLIOMAS, 2018-2030 (USD MILLION)
TABLE 274. DENMARK BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 275. DENMARK BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 276. DENMARK BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 277. DENMARK BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 278. DENMARK BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 279. DENMARK BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 280. DENMARK BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 281. EGYPT BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 282. EGYPT BRAIN & SPINAL CORD CANCER MARKET SIZE, BY GLIOMAS, 2018-2030 (USD MILLION)
TABLE 283. EGYPT BRAIN & SPINAL CORD CANCER MARKET SIZE, BY METASTATIC BRAIN TUMORS, 2018-2030 (USD MILLION)
TABLE 284. EGYPT BRAIN & SPINAL CORD CANCER MARKET SIZE, BY NON-GLIOMAS, 2018-2030 (USD MILLION)
TABLE 285. EGYPT BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 286. EGYPT BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 287. EGYPT BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 288. EGYPT BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 289. EGYPT BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 290. EGYPT BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 291. EGYPT BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 292. FINLAND BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 293. FINLAND BRAIN & SPINAL CORD CANCER MARKET SIZE, BY GLIOMAS, 2018-2030 (USD MILLION)
TABLE 294. FINLAND BRAIN & SPINAL CORD CANCER MARKET SIZE, BY METASTATIC BRAIN TUMORS, 2018-2030 (USD MILLION)
TABLE 295. FINLAND BRAIN & SPINAL CORD CANCER MARKET SIZE, BY NON-GLIOMAS, 2018-2030 (USD MILLION)
TABLE 296. FINLAND BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 297. FINLAND BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 298. FINLAND BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 299. FINLAND BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 300. FINLAND BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 301. FINLAND BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 302. FINLAND BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 303. FRANCE BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 304. FRANCE BRAIN & SPINAL CORD CANCER MARKET SIZE, BY GLIOMAS, 2018-2030 (USD MILLION)
TABLE 305. FRANCE BRAIN & SPINAL CORD CANCER MARKET SIZE, BY METASTATIC BRAIN TUMORS, 2018-2030 (USD MILLION)
TABLE 306. FRANCE BRAIN & SPINAL CORD CANCER MARKET SIZE, BY NON-GLIOMAS, 2018-2030 (USD MILLION)
TABLE 307. FRANCE BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 308. FRANCE BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 309. FRANCE BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 310. FRANCE BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 311. FRANCE BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 312. FRANCE BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 313. FRANCE BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 314. GERMANY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 315. GERMANY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY GLIOMAS, 2018-2030 (USD MILLION)
TABLE 316. GERMANY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY METASTATIC BRAIN TUMORS, 2018-2030 (USD MILLION)
TABLE 317. GERMANY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY NON-GLIOMAS, 2018-2030 (USD MILLION)
TABLE 318. GERMANY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 319. GERMANY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 320. GERMANY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
T

Companies Mentioned

  • Amgen Inc.
  • Bayer AG
  • bluebird bio, Inc.
  • Bristol Myers Squibb Company
  • Dr. Reddy’s Laboratories Ltd.
  • Eisai Inc.
  • F. Hoffmann-La Roche Ltd.
  • Genentech, Inc.
  • GlaxoSmithKline PLC
  • Illumina, Inc.
  • Johnson & Johnson Services, Inc
  • Merck & Co., Inc.
  • Nektar Therapeutics
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Shimadzu Corporation
  • Siemens Healthineers
  • Teva Pharmaceutical Industries Ltd.
  • Y-mAbs Therapeutics A/S

Methodology

Loading
LOADING...

Related Topics

Related Reports

Spinal Cord Neurostimulation Implant Market - Global Forecast to 2030 - Product Image

Spinal Cord Neurostimulation Implant Market - Global Forecast to 2030

  • Report
  • 194 Pages
  • Global
From
Spinal Cord Trauma Treatment - Global Strategic Business Report - Product Image

Spinal Cord Trauma Treatment - Global Strategic Business Report

  • Report
  • 194 Pages
  • Global
From
Acute Spinal Cord Injury Market Report 2025 - Product Image

Acute Spinal Cord Injury Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Spinal Cord Stimulator Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Spinal Cord Stimulator Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 95 Pages
  • Global
From
Nanowired Delivery of Drugs and Antibodies for Neuroprotection in Brain Diseases with Co-Morbidity Factors Part B. International Review of Neurobiology Volume 172 - Product Image

Nanowired Delivery of Drugs and Antibodies for Neuroprotection in Brain Diseases with Co-Morbidity Factors Part B. International Review of Neurobiology Volume 172

  • Book
  • Global
Copyright © 2002-2025 Research and Markets. All Rights Reserved.